AC Immune SA (ACIU) Q1 2026 Earnings Call Transcript

Why It Matters

The results underscore Lilly’s dominant position in the fast‑growing obesity and diabetes space and signal robust earnings upside for investors as the company broadens access and diversifies its pipeline.

Key Takeaways

• Revenue up 56% YoY, driven by Mounjaro, Zepbound
• Koundeo oral GLP-1 approved, 20k patients treated
• Mounjaro holds 60% market share in Brazil, Korea
• Guidance raised to $82‑85 B revenue, EPS $35.5‑$37
• Acquisitions add autoimmune, oncology, neuroscience assets

Pulse Analysis

The obesity‑treatment market is undergoing a paradigm shift as oral GLP‑1 agents like Lilly’s Koundeo enter the United States. By offering a pill that bypasses injection barriers, Koundeo expands the addressable pool of patients who were previously hesitant about injectable therapies. Early adoption metrics—20,000 treated patients and 8,000 prescribers—suggest rapid market penetration, especially as payers such as major PBMs and the CMS Medicare GLP‑1 Bridge program move to cover these drugs. This shift not only deepens Lilly’s foothold in weight‑management but also sets a competitive benchmark for rivals eyeing oral formulations.

Lilly’s financial performance reflects the potency of its incretin franchise. A 56% revenue jump, anchored by $12.8 billion from Mounjaro and Zepbound, pushed non‑GAAP performance margin to 50% and more than doubled non‑GAAP EPS to $8.55. While gross margin slipped marginally due to list‑price erosion, the company offset pricing pressure through volume growth and strategic pricing tactics in self‑pay channels. Internationally, the brand’s expansion into 55+ markets and dominant shares in Brazil and Korea illustrate a resilient growth engine that mitigates reliance on the U.S. market.

Beyond immediate sales, Lilly’s strategic acquisitions—Orna, Centessa, Colonia, and Ajax—inject new therapeutic modalities across autoimmune, oncology, and neuroscience pipelines, diversifying revenue streams beyond cardiometabolic drugs. The raised revenue guidance of $82‑85 billion and EPS target of $35.5‑$37 signal confidence in sustained growth, bolstered by dividend payouts and share‑repurchase programs that enhance shareholder returns. Collectively, these moves position Lilly to capitalize on evolving payer landscapes, expanding global demand for obesity treatments, and a robust pipeline that could drive long‑term earnings momentum.